Biotage Management

Mr. Frederic Vanderhaegen is Chief Executive Officer & President of Biotage AB (publ) from September 16, 2024. Mr. Vanderhaegen joined the Biotage AB (publ) on September 16, 2024. Mr. Frederic was Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Frederic Vanderhaegen	Chief Executive Officer & President	less than a year	no data	no data
Andrew Kellett	Chief Financial Officer	1.2yrs	no data	no data
Anders Wikstrom	Executive Vice President of Operations	14.5yrs	no data	0.0064% SEK 776.0k
Raffaella Bombarda	EVP of Global Marketing	no data	no data	no data
Petra Duprez	Chief Human Resources & Sustainability Officer	no data	no data	0.019% SEK 2.3m
Scott Carr	President of Americas & Chief/Head of Americas	no data	no data	0.010% SEK 1.2m
Jonas Stahlberg	Chief Auditor	no data	no data	no data
Olof Nord	Executive Vice President of Business Development	no data	no data	0.025% SEK 3.0m
Andreas Juhlin	President of International - EMEA and APAC	4.4yrs	no data	0.0064% SEK 776.0k
Magnus Nordstedt	Executive Vice President of IT & Digitalization	no data	no data	0.0059% SEK 708.3k
Lisa Egelrud	Executive Vice President of Quality Assurance & Regulatory Affairs	3.8yrs	no data	no data
Maryam Poorafshar	Executive Vice President R&D	no data	no data	no data

3.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: BIOT's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Torben Jorgensen	Director	5yrs	SEK 857.00k	0.40% SEK 48.3m
Kieran Murphy	Chairman	1.6yrs	SEK 227.00k	no data
Peter von Ehrenheim	Director	11.6yrs	SEK 407.00k	0.020% SEK 2.4m
Asa Hedin	Director	5yrs	SEK 337.00k	no data
Mark Bradley	Director	5.6yrs	SEK 307.00k	no data
Kugan Sathiyanandarajah	Director	1.6yrs	no data	no data
Dan Menasco	Employee Representative Director	2.9yrs	no data	no data
Karen Soerensen	Director	2.6yrs	SEK 357.00k	no data
Par Lundgren	Employee Representative Director	no data	no data	no data
Philip Lamberstam	Employee Representative Director	less than a year	no data	no data

2.9yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BIOT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Biotage Management

Management criteria checks 1/4

Key information

Recent management updates

Biotage AB Appoints Nomination Committee

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

Insider recently bought kr575k worth of stock

Biotage Appoints Andrew Kellett as CFO

Biotage AB (publ) Announces CEO Changes

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Recent updates

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Biotage AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025

Price target decreased by 9.2% to kr173

Biotage AB Appoints Nomination Committee

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) to Report First Half, 2025 Results on Jul 16, 2025

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

Insider recently bought kr575k worth of stock

KKR Reportedly Mulls Options for Stake in Biotage

KKR Reportedly Mulls Options for Stake in Biotage

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 9.6% to kr190

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Price target decreased by 7.1% to kr173

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage AB (Publ) Approves a Dividend, Payable on May 3, 2024

Upcoming dividend of kr1.60 per share

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to kr173

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Dividend of kr1.60 announced

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 23%

Biotage Appoints Andrew Kellett as CFO

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Now 23% overvalued after recent price rise

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Now 22% undervalued

Biotage AB (publ) Announces CEO Changes

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Third quarter 2023 earnings: Revenues in line with analyst expectations

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Consensus EPS estimates fall by 26%

Biotage AB (Publ) Announces Executive Changes

New minor risk - Insider selling

Insider recently sold kr675k worth of stock

Biotage AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Second quarter 2023 earnings: Revenues exceed analyst expectations

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 26%

Price target decreased by 29% to kr180

Now 23% undervalued

New minor risk - Shareholder dilution

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Investor sentiment improves as stock rises 24%

Director recently bought kr2.0m worth of stock

Upcoming dividend of kr1.60 per share at 1.3% yield

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Price target decreased by 12% to kr212

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Consensus EPS estimates fall by 17%, revenue upgraded

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Biotage AB (Publ) Proposes Dividend for 2022

Full year 2022 earnings released: EPS: kr4.06 (vs kr3.14 in FY 2021)